Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Hims & Hers Health Yönetim
Yönetim kriter kontrolleri 2/4
Hims & Hers Health's CEO'su Andrew Dudum, Jan2017 tarihinde atandı, in görev süresi 7.75 yıldır. in toplam yıllık tazminatı $ 14.40M olup, şirket hissesi ve opsiyonları dahil olmak üzere 4.2% maaş ve 95.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 8.83% ine doğrudan sahiptir ve bu hisseler $ 351.98M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.6 yıl ve 2.8 yıldır.
Anahtar bilgiler
Andrew Dudum
İcra Kurulu Başkanı
US$14.4m
Toplam tazminat
| CEO maaş yüzdesi | 4.2% |
| CEO görev süresi | 7.8yrs |
| CEO sahipliği | 8.8% |
| Yönetim ortalama görev süresi | 2.6yrs |
| Yönetim Kurulu ortalama görev süresi | 2.8yrs |
Son yönetim güncellemeleri
Recent updates
Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01
Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25The Market Is Wrong On Hims & Hers Health
Sep 18Hims & Hers: The Current Weakness Creates A Buying Opportunity
Aug 15Hims & Hers Health: Giving Investors Another Bite At The Apple
Aug 01Hims & Hers Health, Inc.'s (NYSE:HIMS) Price In Tune With Revenues
Jul 21Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong
Jul 13Hims & Hers Health: Double-Edged Sword
Jul 02CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$18m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$14m | US$612k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$11m | US$600k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$15m | US$574k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$72m |
| Mar 31 2021 | n/a | n/a | -US$63m |
| Dec 31 2020 | US$27m | US$527k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$25m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$58m |
| Dec 31 2019 | US$254k | US$254k | -US$72m |
Tazminat ve Piyasa: Andrew 'nin toplam tazminatı ($USD 14.40M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.79M ).
Tazminat ve Kazançlar: Andrew 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Andrew Dudum (35 yo)
7.8yrs
Görev süresi
US$14,401,411
Tazminat
Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | US$14.40m | 8.83% $ 337.5m | |
| Chief Financial Officer | 2.8yrs | US$7.43m | 0.097% $ 3.7m | |
| Chief Operating Officer | 3.8yrs | US$6.77m | 0.29% $ 11.1m | |
| Chief Legal Officer & Corporate Secretary | 3.8yrs | US$5.21m | 0.082% $ 3.1m | |
| Chief Medical Officer | 1.8yrs | US$198.26k | 0.098% $ 3.7m | |
| Chief Commercial Officer | less than a year | US$6.71m | 0.090% $ 3.4m | |
| Senior VP | 5.3yrs | US$961.12k | 0.0024% $ 90.2k | |
| Chief Communications Officer | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Human Resources | 2.6yrs | Veri yok | Veri yok | |
| Senior VP & Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Chief Pharmacy & Innovation Officer | 1.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Mental Health | 1.6yrs | Veri yok | Veri yok |
2.6yrs
Ortalama Görev Süresi
44yo
Ortalama Yaş
Deneyimli Yönetim: HIMS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 3.8yrs | US$14.40m | 8.83% $ 337.5m | |
| Chief Medical Officer | 2.7yrs | US$198.26k | 0.098% $ 3.7m | |
| Senior VP & Member of Medical Advisory Board | 2.8yrs | Veri yok | Veri yok | |
| Independent Director | 4.1yrs | US$194.26k | 0.025% $ 961.0k | |
| Lead Independent Director | 4.1yrs | US$227.41k | 0.091% $ 3.5m | |
| Independent Director | 3.6yrs | US$205.51k | 0.034% $ 1.3m | |
| Member of Medical Advisory Board | 2.8yrs | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | 2.8yrs | Veri yok | Veri yok | |
| Member of Medical Advisory Board | 2.8yrs | Veri yok | Veri yok | |
| Member of Medical Advisory Board | 2.8yrs | Veri yok | Veri yok | |
| Member of Medical Advisory Board | 2.8yrs | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: HIMS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.